Despite advances in disease treatment, much of the global population lacks access to these innovations. The pandemic highlighted many of the challenges in production and distribution of medicines to low- and middle-income countries (LMICs), and it demonstrated the importance of access to control infectious diseases. Antimicrobial resistance (AMR) also threatens global health, and resistance in LMICs contributes to what many call the ‘silent pandemic’. People in LMICs have limited antibiotic options, leading to patients being treated with suboptimal or ineffective antibiotics, which contributes to resistance. Recently, agreements were signed between pharmaceutical companies and non-profit organizations that promise to accelerate access to antimicrobial products in LMICs. This panel will cover the structure of these collaborations, describe key aspects for success, and advise on how these efforts can be expanded to bring greater access to more products in the future.